NADAC acquisition cost data for ATENOLOL-CHLORTHALIDONE 100-25. This is a generic medication, typically more affordable than brand-name equivalents.
| NDC | NADAC/Unit | Effective Date | Type |
|---|---|---|---|
| 00591578301 | $0.3910 | 2022-12-21 | Rx |
| 16714093701 | $0.3910 | 2022-12-21 | Rx |
| 29300040101 | $0.3910 | 2022-12-21 | Rx |
| 70710116801 | $0.3910 | 2022-12-21 | Rx |
| 70954039110 | $0.3910 | 2022-12-21 | Rx |
| 00591578301 | $0.3910 | 2022-12-21 | Rx |
| 16714093701 | $0.3910 | 2022-12-21 | Rx |
| 29300040101 | $0.3910 | 2022-12-21 | Rx |
| 70710116801 | $0.3910 | 2022-12-21 | Rx |
| 70954039110 | $0.3910 | 2022-12-21 | Rx |
Generic: Atenolol/Chlorthalidone | Manufacturer: Overall
| Year | Total Spending | Claims | Beneficiaries | Cost/Unit |
|---|---|---|---|---|
| 2019 | $18.6M | 485,712 | 119,047 | $0.5611 |
| 2020 | $19.3M | 462,841 | 112,391 | $0.5869 |
| 2021 | $17.9M | 425,822 | 107,864 | $0.5765 |
| 2022 | $17.3M | 394,683 | 101,497 | $0.5908 |
| 2023 | $15.6M | 368,253 | 95,405 | $0.5624 |
| State | Total Cost | Claims | Beneficiaries |
|---|---|---|---|
| Texas | $1.2M | 26,874 | 7,478 |
| Florida | $1.2M | 28,337 | 7,877 |
| New York | $1.2M | 29,065 | 7,554 |
| Michigan | $955.3K | 21,263 | 5,538 |
| Ohio | $736.5K | 17,431 | 4,568 |
| California | $716.1K | 16,596 | 4,856 |
| Georgia | $676.5K | 16,400 | 4,446 |
| Pennsylvania | $662.4K | 16,996 | 4,381 |
| North Carolina | $608.9K | 14,303 | 3,745 |
| Illinois | $480.4K | 12,934 | 3,468 |
| Tennessee | $452.6K | 11,086 | 3,001 |
| Alabama | $451.7K | 8,964 | 2,410 |
| Indiana | $412.6K | 9,881 | 2,644 |
| South Carolina | $401.3K | 9,767 | 2,552 |
| New Jersey | $391.8K | 9,170 | 2,438 |
| Wisconsin | $379.1K | 7,096 | 1,867 |
| Minnesota | $375.0K | 8,166 | 2,163 |
| Missouri | $317.3K | 7,073 | 1,749 |
| Virginia | $309.2K | 8,519 | 2,350 |
| Maryland | $295.5K | 7,401 | 2,095 |
| Mississippi | $268.4K | 7,727 | 1,879 |
| Louisiana | $266.2K | 7,681 | 1,882 |
| Arkansas | $241.6K | 5,451 | 1,199 |
| Massachusetts | $236.4K | 5,711 | 1,512 |
| Puerto Rico | $224.5K | 6,196 | 1,288 |
| Connecticut | $186.5K | 3,925 | 1,089 |
| Kentucky | $184.0K | 5,752 | 1,430 |
| Oklahoma | $182.9K | 3,499 | 926 |
| Arizona | $142.5K | 3,091 | 924 |
| Washington | $130.4K | 2,705 | 767 |
| Iowa | $130.2K | 3,228 | 813 |
| Colorado | $115.6K | 2,229 | 622 |
| Nebraska | $108.1K | 2,509 | 583 |
| West Virginia | $105.1K | 2,965 | 775 |
| Nevada | $94.2K | 1,940 | 595 |
| Kansas | $89.8K | 2,501 | 606 |
| Oregon | $79.9K | 1,715 | 480 |
| Rhode Island | $55.1K | 1,346 | 357 |
| Utah | $47.2K | 881 | 263 |
| North Dakota | $46.0K | 1,264 | 300 |
| Delaware | $45.8K | 1,263 | 356 |
| Maine | $41.1K | 967 | 288 |
| New Hampshire | $40.5K | 1,051 | 302 |
| New Mexico | $37.1K | 854 | 238 |
| Idaho | $34.8K | 743 | 196 |
| Virgin Islands | $30.0K | 432 | 76 |
| District of Columbia | $28.2K | 607 | 203 |
| South Dakota | $25.9K | 794 | 198 |
| Hawaii | $20.6K | 391 | 114 |
| Vermont | $16.9K | 321 | 90 |
| Montana | $16.5K | 459 | 129 |
| Wyoming | $14.4K | 294 | 76 |
The DrugPricePeek editorial team aggregates and verifies drugs data from CMS NADAC & Medicare Part D. Every statistic on this site is cross-referenced against the official source before publication, with quarterly re-verification cycles.
Read our full methodology or contact us with corrections.